Finn John
Trius Therapeutics, San Diego, CA, USA.
Methods Mol Biol. 2012;841:291-319. doi: 10.1007/978-1-61779-520-6_13.
The emergence of bacteria that are multiply resistant to commonly used antibiotics has created the medical need for novel classes of antibacterial agents. The unique challenges to the discovery of new antibacterial drugs include the following: spectrum, selectivity, low emergence of new resistance, and high potency. With the emergence of genomic information, dozens of antibacterial targets have been pursued over the last 2 decades often using SBDD. This chapter reviews the application of structure-based drug design approaches on a selected group of antibacterial targets (DHFR, DHNA, PDF, and FabI) where significant progress has been made. We compare and contrast the different approaches and evaluate the results in terms of the biological profiles of the leads produced. Several common themes have emerged from this survey, resulting in a set of recommendations.
对常用抗生素具有多重耐药性的细菌的出现,引发了医学上对新型抗菌剂的需求。发现新型抗菌药物面临的独特挑战包括以下几点:抗菌谱、选择性、低新耐药性的出现以及高效能。随着基因组信息的出现,在过去20年里,人们常常利用基于结构的药物设计(SBDD)来寻找数十种抗菌靶点。本章回顾了基于结构的药物设计方法在一组选定的抗菌靶点(二氢叶酸还原酶、二氢蝶酸合酶、肽脱甲酰基酶和脂肪酸生物合成酶I)上的应用,在这些靶点上已经取得了显著进展。我们比较并对比了不同的方法,并根据所产生的先导化合物的生物学特性评估了结果。从这项调查中出现了几个共同的主题,从而得出了一系列建议。